Tag: Orilissa

Visanne, the brand name for the active ingredient dienogest, is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of endometriosis. Consequently, there is no official retail price for **Visanne cost in the US** through domestic pharmacies. However, patients may source the medication from international online pharmacies, where prices can vary widely.

While Visanne (dienogest) is approved for treating endometriosis in Europe, Canada, Australia, and Japan, it has not been approved by the U.S. Food and Drug Administration (FDA) [1.2.1, 1.3.1]. This raises a critical question for many: why is Visanne not available in the US?

Endometriosis affects an estimated 10 to 15 percent of reproductive-aged women, often causing debilitating pain. For those experiencing moderate to severe pain from this condition, the oral medication Orilissa offers a targeted treatment approach. To understand what exactly does Orilissa do, one must look at its specific action on the body's hormonal pathways.